Skip to main content
SpringerLink
Log in

Konservative Adipositastherapie

Conservative obesity therapy

  • Leitthema
  • Published:
Die Diabetologie Aims and scope

Zusammenfassung

Die stetig steigende Adipositasprävalenz stellt eine der größten (gesundheitsökonomischen) Herausforderungen unseres Jahrhunderts dar. In den letzten Jahren hat sich durch intensivierte Forschung nicht nur das wissenschaftlich-medizinische Verständnis der Erkrankung Adipositas grundlegend verändert, sondern es konnten hierdurch auch neue Therapieoptionen entwickelt werden. Basierend auf der Erkenntnis, dass Adipositas eine durch Veränderungen des zentralen Nervensystems geprägte Erkrankung ist, stellen unter den konservativen Therapieoptionen die medikamentöse Therapie mit GLP-1-Analoga (GLP-1: glukagonähnliches Peptid 1), spezielle Patientenschulungsprogramme und digitale Gesundheitsanwendungen (DiGA) die Hauptschwerpunkte dar. Neben den genannten Behandlungsansätzen stehen eine adäquate evidenzbasierte Patientenaufklärung und -edukation hinsichtlich der Erkrankung im Vordergrund.

Abstract

The continuously increasing prevalence of obesity represents one of the most significant health-economic challenges of our century. In recent years, intensified research has not only fundamentally altered the scientific and medical understanding of the disease obesity but has also led to the development of new therapeutic options. Based on the realization that obesity is a disease characterized by alterations in the central nervous system, among the conservative therapeutic options, pharmacotherapy—for example, glucagon-like peptide‑1 (GLP-1) analogs—as well as specific patient education programs and digital health applications (DiGA) are the main foci. In addition to the mentioned treatment approaches, adequate evidence-based patient education and enlightenment concerning the disease are of utmost importance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Cefalu WT, Bray GA, Home PD et al (2015) Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors’ Expert Forum. Diabetes Care 38(8):1567–1582

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Marchesini G, Montesi L, El Ghoch M, Brodosi L, Calugi S, Dalle Grave R (2016) Long-term weight loss maintenance for obesity: a multidisciplinary approach. Diabetes Metab Syndr Obes

  3. Kraschnewski JL, Boan J, Esposito J et al (2010) Long-term weight loss maintenance in the United States. Int J Obes 34(11):1644–1654

    Article  CAS  Google Scholar 

  4. Effertz T, Engel S, Verheyen F, Linder R (2016) The costs and consequences of obesity in Germany: a new approach from a prevalence and life-cycle perspective. Eur J Health Econ 17(9):1141–1158

    Article  PubMed  Google Scholar 

  5. Wangler J, Jansky M (2020) Betreuungsbedürfnisse von Patienten mit Übergewicht und Adipositas in der Hausarztpraxis – Ergebnisse einer Interviewstudie. Präv Gesundheitsf 16(4):273–281

    Article  Google Scholar 

  6. Thanarajah ES, DiFeliceantonio AG, Albus K et al (2023) Habitual daily intake of a sweet and fatty snack modulates reward processing in humans. Cell Metab 35(4):571–584 e6

    Article  Google Scholar 

  7. McDougle M, de Araujo A, Singh A et al (2024) Separate gut-brain circuits for fat and sugar reinforcement combine to promote overeating. Cell Metab

  8. Mazzone CM, Liang-Guallpa J, Li C et al (2020) High-fat food biases hypothalamic and mesolimbic expression of consummatory drives. Nat Neurosci 23(10):1253–1266

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. van Bloemendaal L, Veltman DJ, Ten Kulve JS et al (2015) Brain reward-system activation in response to anticipation and consumption of palatable food is altered by glucagon-like peptide‑1 receptor activation in humans. Diabetes Obes Metab 17(9):878–886

    Article  PubMed  Google Scholar 

  10. Wirth A, Wabitsch M, Hauner H (2014) The prevention and treatment of obesity. Dtsch Ärztebl Int 111(42):705–713

    PubMed  PubMed Central  Google Scholar 

  11. Gudzune KA, Doshi RS, Mehta AK et al (2015) Efficacy of Commercial Weight-Loss Programs. Ann Intern Med 162(7):501–512

    Article  PubMed  PubMed Central  Google Scholar 

  12. Becker C, Walle H (2020) 5‑Jahres-Ergebnisse eines ambulanten, ärztlich betreuten Adipositastherapieprogramms. Aktuel Ernahrungsmed 45(03):161–171

    Article  Google Scholar 

  13. Berg A, Berg A, Frey I, König D, Predel H‑G (2008) Exercise Based Lifestyle Intervention in Obese Adults—Results of the Intervention Study M.O.B.I.L.I. S. Dtsch Ärztebl Int

  14. Albus K, Kohlenbach L, Hanssen R et al (2020) Erfolgreiche Lebensstiländerung für schwer adipöse Patienten – Eine kontrollierte Studie zur Evaluation eines Patientenschulungsprogramms. Diabetol Stoffwechs 15(02):157–164

    Article  Google Scholar 

  15. Ard JD, Lewis KH, Rothberg A et al (2019) Effectiveness of a Total Meal Replacement Program (OPTIFAST Program) on Weight Loss: Results from the OPTIWIN Study. Obesity 27(1):22–29

    Article  PubMed  Google Scholar 

  16. Montesi L, El Ghoch M, Brodosi L, Calugi S, Marchesini G, Dalle Grave R (2016) Long-term weight loss maintenance for obesity: a multidisciplinary approach. Diabetes Metab Syndr Obes 9:37–46

    PubMed  PubMed Central  Google Scholar 

  17. Ryan DH, Espeland MA, Foster GD et al (2003) Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials 24(5):610–628

    Article  PubMed  Google Scholar 

  18. Roth L, Ordnung M, Forkmann K, Mehl N, Horstmann A (2023) A randomized-controlled trial to evaluate the app-based multimodal weight loss program zanadio for patients with obesity. Obesity 31(5):1300–1310

    Article  PubMed  Google Scholar 

  19. Gemesi K, Winkler S, Schmidt-Tesch S, Schederecker F, Hauner H, Holzapfel C (2023) Efficacy of an app-based multimodal lifestyle intervention on body weight in persons with obesity: results from a randomized controlled trial. Int J Obes Relat Metab Disord 48(1):118–126

    Article  Google Scholar 

  20. Davidson MH, Hauptman J, DiGirolamo M et al (1999) Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 281(3):235–242

    Article  CAS  PubMed  Google Scholar 

  21. Leblanc ES, O’Connor E, Whitlock EP, Patnode CD, Kapka T (2011) Effectiveness of primary care-relevant treatments for obesity in adults: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 155(7):434–447

    Article  PubMed  Google Scholar 

  22. Secher A, Jelsing J, Baquero AF et al (2014) The arcuate nucleus mediates GLP‑1 receptor agonist liraglutide-dependent weight loss. J Clin Invest 124(10):4473–4488

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Pi-Sunyer X, Astrup A, Fujioka K et al (2015) A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med 373(1):11–22

    Article  PubMed  Google Scholar 

  24. Rubino DM, Greenway FL, Khalid U et al (2022) Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA 327(2):138–150

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Rubino DM, Greenway FL, Khalid U et al (2022) Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes. JAMA 327(2)

  26. Mok J, Adeleke MO, Brown A et al (2023) Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery: The BARI-OPTIMISE Randomized Clinical Trial. JAMA Surg 158(10):1003–1011

    Article  PubMed  PubMed Central  Google Scholar 

  27. Filippatos TD, Panagiotopoulou TV, Elisaf MS (2014) Adverse Effects of GLP‑1 Receptor Agonists. Rev Diabet Stud 11(3-4):202–230

    Article  PubMed  Google Scholar 

  28. Yoshida Y, Joshi P, Barri S et al (2022) Progression of retinopathy with glucagon-like peptide‑1 receptor agonists with cardiovascular benefits in type 2 diabetes—A systematic review and meta-analysis. J Diabetes Complicat 36(8)

  29. Nagendra L, Bg H, Sharma M, Dutta D (2023) Semaglutide and cancer: A systematic review and meta-analysis. Diabetes Metab Syndr 17(9):102834

    Article  CAS  PubMed  Google Scholar 

  30. - (2024) Semaglutide and risk of suicidal ideations. Nat Med 30(1):45–46

    Article  PubMed  Google Scholar 

  31. Lincoff AM, Brown-Frandsen K, Colhoun HM et al (2023) Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 389(24):2221–2232

    Article  CAS  PubMed  Google Scholar 

  32. Wilding JPH, Batterham RL, Davies M et al (2022) Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab 24(8):1553–1564

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Aronne LJ, Sattar N, Horn DB et al (2024) Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity. JAMA 331(1)

  34. Jastreboff AM, Aronne LJ, Ahmad NN et al (2022) Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 387(3):205–216

    Article  CAS  PubMed  Google Scholar 

  35. Jastreboff AM, Kaplan LM, Frias JP et al (2023) Triple-Hormone-Receptor Agonist Retatrutide for Obesity—A Phase 2 Trial. N Engl J Med 389(6):514–526

    Article  CAS  PubMed  Google Scholar 

  36. Jain SS, Ramanand SJ, Ramanand JB, Akat PB, Patwardhan MH, Joshi SR (2011) Evaluation of efficacy and safety of orlistat in obese patients. Indian J Endocrinol Metab 15(2):99–104

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Astrup A, Carraro R, Finer N et al (2012) Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP‑1 analog, liraglutide. Int J Obes 36(6):843–854

    Article  CAS  Google Scholar 

  38. Astrup A, Rossner S, Van Gaal L et al (2009) Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 374(9701):1606–1616

    Article  CAS  PubMed  Google Scholar 

  39. Mehta A, Marso SP, Neeland IJ (2016) Liraglutide for weight management: a critical review of the evidence. Obes Sci Pract 3(1):3–14

    Article  PubMed  PubMed Central  Google Scholar 

  40. Jensterle M, Rizzo M, Haluzik M, Janez A (2022) Efficacy of GLP‑1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review. Adv Ther 39(6):2452–2467

    Article  PubMed  PubMed Central  Google Scholar 

  41. Verma S, Poulter NR, Bhatt DL et al (2018) Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke. Circulation 138(25):2884–2894

    Article  CAS  PubMed  Google Scholar 

  42. Davies M, Pieber TR, Hartoft-Nielsen M‑L, Hansen OKH, Jabbour S, Rosenstock J (2017) Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes. JAMA 318(15)

  43. Ghusn W, De la Sacoto RAD et al (2022) Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity. JAMA Netw Open 5(9):e2231982

    Article  PubMed  PubMed Central  Google Scholar 

  44. Krishnaswami A, Ashok R, Sidney S et al (2018) Real-World Effectiveness of a Medically Supervised Weight Management Program in a Large Integrated Health Care Delivery System: Five-Year Outcomes. Perm J 22:17–82

    Article  PubMed  PubMed Central  Google Scholar 

  45. Look ARG (2014) Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study. Obesity 22(1):5–13

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Fakultät und Universitätsklinikum Köln, Poliklinik für Endokrinologie, Diabetologie und Präventivmedizin (PEPD), Universität zu Köln, Köln, Deutschland

    Alina C. Kretschmer,  Sita Arjune &  Ruth Hanßen

  2. Max-Planck-Institut für Stoffwechselforschung, Köln, Deutschland

    Ruth Hanßen

Authors
  1. Alina C. Kretschmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sita Arjune
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ruth Hanßen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Alina C. Kretschmer, Sita Arjune or Ruth Hanßen.

Ethics declarations

Interessenkonflikt

R. Hanßen hat Referentenhonorare oder geldwerte Leistungen von Novo Nordisk GmbH erhalten. A.C. Kretschmer und S. Arjune geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autorinnen keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

Hinweis des Verlags

Der Verlag bleibt in Hinblick auf geografische Zuordnungen und Gebietsbezeichnungen in veröffentlichten Karten und Institutsadressen neutral.

Die Autorinnen Alina C. Kretschmer und Sita Arjune haben zu gleichen Teilen zum Manuskript beigetragen.

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kretschmer, A.C., Arjune, S. & Hanßen, R. Konservative Adipositastherapie. Diabetologie 20, 333–339 (2024). https://doi.org/10.1007/s11428-024-01160-6

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11428-024-01160-6

Schlüsselwörter

Keywords

Search

Navigation